首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1629601

迷幻藥市場：依藥物類型、用途、通路、給藥途徑及地區分類

Psychedelic Drugs Market, By Drug Type, By Application, By Distribution Channel, By Route of administration, By Geography

出版日期: 2024年11月26日 | 出版商:

Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球迷幻藥市場規模估計為 34.1 億美元，預計到 2031 年將達到 83.2 億美元，2024 年至 2031 年的複合年成長率為 13.6%。

報告範圍		報告詳細資訊
基準年	2023	2024 年的市場規模	34.1億美元
效能資料	2019 年至 2023 年	預測期	2024 年至 2031 年
預測期間 2024 年至 2031 年複合年成長率：	13.60％	2031 年價值預測	83.2億美元

圖。

近年來，隨著迷幻藥輔助心理治療在精神疾病治療中的接受度不斷提高，全球迷幻藥市場經歷了顯著成長。迷幻藥，例如麥角酸二乙醯胺 (LSD)、裸蓋菇素、3,4-亞甲基安非他命(MDMA)、氯胺酮和分離性藥物，用於改變使用者的感知、思想和意識層級。憂鬱症和其他精神疾病的盛行率不斷上升，以及評估迷幻藥治療各種精神疾病療效的臨床研究數量不斷增加，是推動市場成長的主要因素。此外，北美和歐洲多個政府採取的有利監管改革也對迷幻藥在治療抗治療性憂鬱症等疾病方面的應用產生了積極影響。

市場動態：

全球迷幻藥市場的成長主要受以下因素推動：精神疾病盛行率不斷上升、迷幻藥相關的藥物開發和臨床研究不斷進行、以及醫生和患者對迷幻藥輔助心理治療的接受度不斷提高。世界衛生組織估計，全球整體有超過2.64億人患有憂鬱症。迷幻藥，例如裸蓋菇素、LSD 和 MDMA，已顯示出治療重度憂鬱症和其他精神疾病的潛力。越來越多的臨床研究評估這些藥物對抗治療性憂鬱症（TRD）和創傷後壓力症候群（PTSD）等疾病的治療效果，從而推動市場成長。此外，一些新興經濟體的法律規範允許迷幻藥進一步商業化。然而，有關這些藥物的臨床和商業性使用的嚴格規定給市場帶來了潛在的挑戰。此外，娛樂用途合法化的風險可能會抑制迷幻藥的治療應用。另一方面，透過加強研究和創新開拓實證治療模式為該市場的相關人員提供了機會。

本研究的主要特點

本報告對全球精神藥物市場進行了詳細分析，並提供了預測期（2024-2031 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設基準年為 2023 年。

它還強調了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球迷幻藥市場的主要企業。

研究中介紹的主要企業包括 MindMed、Compass Pathways、Cybin、Atai Life Sciences、Field Trip Health、Havn Life Sciences、Revive Therapeutics、NeonMind Biosciences、Numinus Wellness、PharmaTher Holdings、Jazz Pharmaceuticals、Seelos Therapeutics、NRx Pharmauticals、Psychednesss、Psychednessed。

本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。

全球迷幻藥市場報告涵蓋該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員可以透過用於分析全球迷幻藥市場的各種策略矩陣來簡化決策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	US$ 3.41 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	13.60%	2031 Value Projection:	US$ 8.32 Bn

The global psychedelic drugs market has witnessed significant growth in the past few years due to the increasing acceptance of psychedelic-assisted psychotherapy for the treatment of mental health conditions. Psychedelic drugs such as lysergic acid diethylamide (LSD), psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), ketamine, and dissociative drugs are used to alter users' perceptions, thoughts, and consciousness levels. Increasing prevalence of depression and other mental disorders as well as growing number of clinical research to evaluate the efficacy of psychedelic drugs for treatment of various mental health disorders is primarily driving the market growth. Moreover, favorable regulatory reforms by several governments across North America and Europe have positively impacted the adoption of psychedelic therapeutics for treatment of conditions such as treatment-resistant depression.

Market Dynamic:

The global psychedelic drugs market growth is primarily driven by factors such the increasing prevalence of mental disorders, ongoing drug development and clinical research related to psychedelic drugs, and growing acceptance of psychedelic-assisted psychotherapy among physicians and patients. According to the WHO estimates, over 264 million people suffer from depression globally. Psychedelic drugs such as psilocybin, LSD, and MDMA have shown potential for the treatment of major depressive disorder as well as other mental health conditions. The growing number of clinical studies to evaluate the therapeutic effects of these drugs for conditions like treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD) is fostering the market growth. Additionally, supportive regulatory framework in several developed economies is enabling the commercialization of psychedelic medicines. However, strict regulations regarding the clinical and commercial use of these drugs pose potential challenges for the market. Moreover, risk of legalized recreational use can restrain the therapeutic adoption of psychedelic drugs. Meanwhile, the development of evidence-based treatment paradigms by facilitating research and innovation represents an opportunity for stakeholders in this market.

Key features of the study:

This report provides an in-depth analysis of the global psychedelic drugs market and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global psychedelic drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include MindMed, Compass Pathways, Cybin Inc., Atai Life Sciences, Field Trip Health Ltd., Havn Life Sciences, Revive Therapeutics, NeonMind Biosciences, Numinus Wellness, PharmaTher Holdings Ltd., Jazz Pharmaceuticals, Seelos Therapeutics, NRx Pharmaceuticals Inc., Psyched Wellness Ltd., and Silo Wellness,

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global psychedelic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global psychedelic drugs market.

Market Segmentation

By Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
- Gamma Hydroxybutyric Acid (GHB)
- Ketamine
- Psilocybin
- Lysergic Acid Diethylamide (LSD)
- 3,4-Methylenedioxymethamphetamine (MDMA)
- Other Drug Types (Mescaline, etc.)
By Application Insights (Revenue, USD Bn, 2019 - 2031)
- Mental Health Disorders
- Depression
- Anxiety
- PTSD (Post-Traumatic Stress Disorder)
- Substance Use Disorders
- Neurological Disorders
- Alzheimer's Disease
- Parkinson's Disease
- Pain Management:
- Chronic Pain
- Migraines
- Other Applications:
- Obsessive-Compulsive Disorder (OCD)
- Others (Opiate Addiction, etc.)
By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Intravenous
- Inhalation
- Intranasal
- Others (Rectal)
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- MindMed
- Compass Pathways
- Cybin Inc.
- Atai Life Sciences
- Field Trip Health Ltd.
- Havn Life Sciences
- Revive Therapeutics
- NeonMind Biosciences
- Numinus Wellness
- PharmaTher Holdings Ltd.
- Jazz Pharmaceuticals
- Seelos Therapeutics
- NRx Pharmaceuticals Inc.
- Psyched Wellness Ltd.
- Silo Wellness

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Psychedelic Drugs Market, By Drug Type
- Global Psychedelic Drugs Market, By Application
- Global Psychedelic Drugs Market, By Distribution Channel
- Global Psychedelic Drugs Market, By Route of Administration
- Global Psychedelic Drugs Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Psychedelic Drugs Market, By Drug Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Gamma Hydroxybutyric Acid (GHB)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Ketamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Psilocybin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Lysergic Acid Diethylamide (LSD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
3,4-Methylenedioxymethamphetamine (MDMA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Other Drug Types (Mescaline, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Psychedelic Drugs Market, By Application, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Mental Health Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Depression
Anxiety
PTSD (Post-Traumatic Stress Disorder)
Substance Use Disorders
Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Alzheimer's Disease
Parkinson's Disease
Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Chronic Pain
Migraines
Other Applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Obsessive-Compulsive Disorder (OCD)
Others (Opiate Addiction, etc.)

6. Global Psychedelic Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Psychedelic Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others (Rectal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Psychedelic Drugs Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

MindMed
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Compass Pathways
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cybin Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Atai Life Sciences
Field Trip Health Ltd.
Havn Life Sciences
Revive Therapeutics
NeonMind Biosciences
Numinus Wellness
PharmaTher Holdings Ltd.
Jazz Pharmaceuticals
Seelos Therapeutics
NRx Pharmaceuticals Inc.
Psyched Wellness Ltd.
Silo Wellness